Hematology/Oncology

Top Story

Melanoma in situ incidences increase at faster rate than invasive melanoma

July 27, 2016

Incidence of melanoma in situ increased at a faster rate than invasive melanoma, with the two melanomas displaying epidemiological and clinical differences, according to recently published study results.

Researchers used the Nurses’ Health Study, an ongoing prospective of cohort of 121,700 female registered nurses (1976-2010), and the Health Professionals Follow-up Study, which includes 51,529 men (aged 40 to 75 years) in the health care profession to prospectively collect incident cases of melanoma (1986-2010).

In the Journals

Statin use associated with dose-dependent reduction in cirrhosis and HCC in patients with HCV

July 27, 2016
In patients with hepatitis C, both atorvastatin and fluvastatin use were associated with a dose-dependent reduction in both cirrhosis and hepatocellular carcinoma…
At Issue

Ibrutinib, idelalisib, venetoclax provide ‘very exciting developments’ in CLL

July 27, 2016
Recent discoveries involving ibrutinib, idelalisib and venetoclax have had a tremendous impact on life expectancy and quality of life in patients with chronic…

ASTRO elects five board members

July 27, 2016
The American Society for Radiation Oncology elected new officers to the society’s board of directors. Paul M. Harari, MD, FASTRO, chair of the department…
In the Journals Plus

Multiple mental health symptoms common in adolescent cancer survivors

July 27, 2016
Adolescent survivors of childhood cancers frequently experienced concurrent behavioral, emotional and social deficits, according to research published in Journal of
More News Headlines »
CME

The Patient with Severe Leukocytosis

No commercial support for this activity.

Currently five tyrosine kinase inhibitors are available for use in patients with chronic myeloid leukemia (CML)…
More »
Video
At Issue

VIDEO: Multiple myeloma treatments evolve as access to new technology improves

July 12, 2016
More »
Featured
2016 ASCO Annual Meeting

2016 ASCO Annual Meeting

CME

The Patient with Lymphadenopathy

No commercial support for this activity.

Castleman’s disease is a rare lymphoproliferative disorder that is characterized by enlargement of 1 (unicentric) or…
More »
Current Issues
View the Current Issue
HemOnc Today